medigraphic.com
ISSN 0028-3851 (Print)

2005, Number 4

<< Back Next >>

Rev Neurol Neurocir Psiquiat 2005; 38 (4)

Importance gieven by the psychiatrist to treatment compliance in psychotics patients

Garcia R, Mazza R, Martins NE, Ramos AM, de Oliveira SM, Santos AF, Garcia LM

Language: Portugués
References: 18
Page: 129-134
PDF size: 65.76 Kb.


Text Extraction

Background. The interest in treatment compliance theme in psychotic patients has been increasing due to the difficulties the health professionals are facing in dealing with patients who do not follow prescriptions that are recommended to them. Objective. To evaluate the priority given by psychiatrists to treatment compliance of psychotic patients, as well as the importance given to other symptoms by order of severity. Methods. A structured questionnaire that was randomly applied, in the period between April and July 2003, to 54 psychiatrists with professional practices in Salvador, Bahia. Literature from 1993 to 2003 was studied, including articles, summaries, through Medline computerized research. No conclusive data were found in our revision. Results. In the questionnaire evaluation, 18.8% considered refusal to take medication as a main item and 37% thought the first two items as the most important; 78% considered agitation/aggressiveness as priority; 34.4% regarded suicide risk as the main item; 3.1% considered delusion and hallucination as priority. Conclusion. Treatment compliance was not considered as priority by most of the psychiatrists, and the longer they have been active in practice, the less importance was given to compliance.
It is important to design a relationship between the professionals and the family in order to make a mutual commitment.


REFERENCES

  1. Blackwell B. Treatment adherence. Br J Psychiatry 1976; 129:513-31.

  2. Garcia R. Papel da Motivação na Adesão ao Tratamento Psiquiátrico. Rev Bras Neurol Psiq, 2001; 5(3); 97-101).

  3. Butter C, Rollnick S, Stott N. The practitioner, the patient and resistance to change: recent ideas on compliance. Can Med Assoc J 1996; 154: 1357-67.

  4. Garcia R, Schooley RT, Badaró R. An adherence trilogy is essential for long-term HAART success. Brazil J Infect Diseas 2003; 7(5): 307-14.

  5. Weiden PJ, Mott T, Curcio N. Recognition and management of neuroleptic noncompliance. In Contemporary issues in the treatment of schizophrenia. Washington, DC: Shirqui C, Nasrallah H. (eds.) American Psychiatry Association Press, 1995; 411-34.

  6. Gerhardt U. Ideas about illness. New York: New York University Press; 1989; In: Adesão a tratamentos médicos. Santos JQ Psiq Prat Med 2000; 33(1): 14-6.

  7. Santos JQ. Adesão a tratamentos médicos. Psiq Prat Méd. 2000; 33(1): 14-6.

  8. Leppik IE. How to get patients with epilepsy to take their medication: The problem of noncompliance. Postgrad Med 1990; 88: 253-6.

  9. Rittmannsberger H, Packinger T, Keppelmuller P, Wancata J. Medication adherence among psychotic patients. Psychiatr Service February 2004; 55: 174-9.

  10. Green LW, Simons-Morton DG. Denial, delay and disappointment: Discovering and overcoming the causes of drug errors and missed appointments (chap 1). In: Schmidt D, Leppik IE, (eds.) Compliance in epilepsy. New York, NY. Elsevier Science Publishers. BV (Biomedical Division); 1988: 7-21.

  11. Misdrahi D, Llorca PM, Lancon C, Bayle FJ. Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications. Encephale 2002; May-Jun; 28:266-72.

  12. Medication Regimens: causes of non compiance. Washington, D.C.; Office of the Inspector General, Department of Health and Human Services. 1990; June: 12-14.

  13. Roose SP “Compliance: the impact of adverse events and tolerability on the physician’s treatment decisions”. Eur Neuropsychopharmacol. 2003; 13 Sppl: 585-592.

  14. Van Putten T, May PRA. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychiatry 1978; 35: 477-480.

  15. Van Putten T, May PRA, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981; 38: 187-190.

  16. Hogan TP, Awad AG. Pharmacotherapy and suicide risk in schizophrenia . Can J Psychiatry 1983; 28: 277-281.

  17. Naber D, Walther A, Kirchere T, et al. In Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Edited by Gaebel W, Awad AG. Heidelberg: Springer-Verlag 1994; pp. 111-22.

  18. Gabbard GO, Kay J. The fate of integrated treatment: what ever happened to the biopsychosocial psychiatrist? Am J Psychiatry 2001; 158: 1956-63.




2020     |     www.medigraphic.com